Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Virax Biolabs Group's Other Operating Expense for the
six
months ended in Mar. 2026 was $-0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00 Mil.
Virax Biolabs Group's quarterly Other Operating Expense
declined
from Mar. 2025 ($-0.00 Mil) to Sep. 2025 ($-0.00 Mil) but then
stayed the same
from Sep. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).
Virax Biolabs Group's annual Other Operating Expense
increased
from Mar. 2024 ($0.00 Mil) to Mar. 2025 ($0.00 Mil) and
increased
from Mar. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).
Virax Biolabs Group Other Operating Expense Related Terms
Virax Biolabs Group Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of $-0.00 Mil mean?
Virax Biolabs Group (VRAX) has a Other Operating Expense of $-0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Other Operating Expense too high?
Virax Biolabs Group's current Other Operating Expense is $-0.00 Mil. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Other Operating Expense compare to ISCO and PKTX?
Virax Biolabs Group's Other Operating Expense of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current Other Operating Expense is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.61, compared to a current price of $2.62 — trading 27.4% below its estimated fair value. The current Other Operating Expense is $-0.00 Mil. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Other Operating Expense is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued.
The current stock price of $2.62 is trading 27.4% below its estimated GF Value™ of $3.61.
GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.
Key valuation signals for VRAX:
Other Operating Expense: $-0.00 Mil
GF Value™: $3.61 vs. price of $2.62 (27.4% below fair value)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score
Get the complete analysis for VRAX
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
